Last updated: June 27, 2026
IFEX/MESNEX KIT (ifosfamide + mesna) suppliers: What companies make the kit components and who supplies in-market products?
Executive summary:
IFEX/MESNEX KIT is an ifosfamide chemotherapy product supplied as a kit with mesna uroprotectant. The kit’s supply chain typically maps to (1) the ifosfamide drug substance and drug product manufacturer(s), (2) mesna drug substance and drug product manufacturer(s), and (3) the kit assembler/labeler that packages the two components into a single commercial “kit” product for FDA distribution. Without the specific manufacturer/labeler and NDC mapping for the exact commercial presentation(s) of IFEX/MESNEX KIT in the U.S. and/or specific geographies, a complete, accurate supplier list cannot be produced.
Who supplies IFEX/MESNEX KIT in the U.S. (NDC) and who are the kit labelers?
Featured snippet answer: IFEX/MESNEX KIT supply is split between the kit labeler (who holds the marketed presentation) and the underlying drug-product/kit component manufacturers (ifosfamide and mesna).
Kit supply chain structure
- Kit labeler / marketing authorization holder (MAH): Packages and releases the commercial kit that combines ifosfamide and mesna dosing.
- Ifosfamide component supplier: Manufactures the ifosfamide sterile dosage form used in the kit.
- Mesna component supplier: Manufactures mesna sterile dosage form used in the kit.
- Kit packager/assembler (may be the same as MAH): Physically forms the kit under the MAH’s quality system.
Typical supplier documentation used in diligence
- FDA labeling and package insert manufacturing sections (identify manufacturer and/or “manufactured for” entities)
- NDC directory listing (ties to labeler and product presentation)
- Orange Book entry (if listed) and FDA product database records (ties to NDA/labeler)
- Commercial distributor listings (can show “sold by” vs “manufactured by”)
What companies manufacture ifosfamide (drug product) used in IFEX/MESNEX KIT?
Featured snippet answer: The ifosfamide kit component is supplied by one or more sterile manufacturing sites capable of producing cytotoxic ifosfamide under GMP and packaging for oncology distribution.
Ifosfamide manufacturing categories
- Sterile drug product manufacturers (vial/bottle filling and finishing)
- Primary packaging suppliers (glass container, elastomer closures, cartons, kit overwrap)
- Contract manufacturing organizations (CMOs) for sterile filling, labeling, and release
What to extract to build a true supplier list
- Site-specific “manufactured by” / “manufactured for” entities in IFEX kit labeling
- NDA/labeler-specific facility names tied to NDCs
Which mesna suppliers make the mesna component used in IFEX/MESNEX KIT?
Featured snippet answer: The mesna component supplier is the sterile mesna manufacturer identified in kit labeling and FDA product records for the corresponding kit NDC/presentation.
Mesna supplier documentation targets
- Label insert “manufactured for” and “manufactured by” names
- Mesna presentation strength/concentration mapping to the kit NDC
How do kit component suppliers change by NDC, strength, or packaging presentation?
Featured snippet answer: Supplier and manufacturing site names can change by NDC, dosage presentation, or over time due to site transfers and contract manufacturing.
Why supplier lists vary
- The same brand/kit concept can have multiple NDCs with different labelers or manufacturing sites
- Labeling updates can swap CMOs while keeping the same brand presentation
- Distribution can be national vs hospital channel with different “sold by” entities
What a correct diligence timeline captures
- NDC revisions across time
- Manufacturer/site transitions referenced in labeling revisions
What patents or exclusivity affect IFEX/MESNEX KIT supply and generic risk?
Featured snippet answer: IP and exclusivity do not directly determine supplier identity, but they do determine whether alternatives are allowed to enter the market through ANDA pathways, which in turn changes supplier competition and switching.
Licensing and entry pathways that impact procurement
- Brand kit consolidation can reduce eligible manufacturing competition
- Generic or authorized alternatives (if any) can reconfigure supplier sourcing and hospital contracting
(No patent/exclusivity mapping is provided here because the input does not specify the NDA/active ingredient presentation or the exact IFEX/MESNEX kit product record to anchor an Orange Book/patent estate pull.)
Which countries and distributors supply IFEX/MESNEX KIT outside the U.S.?
Featured snippet answer: Non-U.S. supply is typically handled by local marketing authorizations or distributors, with component manufacturing often still originating from a limited number of sterile GMP sites.
Geographic supplier mapping approach
- Identify each country’s MAH and local distributor from regulatory filings and labels
- Map back to component manufacturer sites from product labels and wholesaler pack data
(A supplier list by country requires the exact geography scope and NDC/National Drug codes or local registration identifiers.)
Key Takeaways
- IFEX/MESNEX KIT sourcing depends on the kit labeler/assembler plus separate ifosfamide and mesna sterile component manufacturers.
- A complete, accurate “who supplies” answer requires anchoring to the exact commercial presentations (NDC and/or country registrations) because manufacturer/site names can vary by presentation and over time.
- Without the specific IFEX/MESNEX KIT product record(s) to tie to FDA labeling and NDC listings, providing a definitive supplier roster would be incomplete.
FAQs
- How do I identify the kit labeler for IFEX/MESNEX KIT by NDC?
- What is the difference between “manufactured for” and “manufactured by” on IFEX/MESNEX KIT packaging?
- Can the ifosfamide or mesna component manufacturer change while keeping the same brand kit?
- What documents show the actual sterile manufacturing site for oncology kit components?
- How does procurement differ between hospital distribution and specialty pharmacy channels for IFEX/MESNEX KIT?
References
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Website).
- U.S. FDA. National Drug Code (NDC) Directory. (Website).
- U.S. FDA. Drugs@FDA: FDA-Approved Drugs. (Website).
